Saúde
Pertuzumab poderá passar a ser a última linha na ampliação da vida de pacientes com câncer de próstata. Há muitos anos, o tratamento hormonal foi introduzido quando os demais tratamentos convencionais não curavam o câncer, que voltava. Não cura, mas aumenta a sobrevida em muitos meses até alguns anos. Taxotere foi adicionado depois, o que representoumais alguns meses de vida. Agora está sendo testado o pertuzumab.Um pequeno teste revelou que a droga prolongou a vida em 16,4 meses em um grupo que já havia tentado tudo o que havia para tentar. Entre os que não tomaram pertuzumab, a mediana até a morte foi de 10,7 meses. Um ganho de quase seis meses. Notícia mais detalhada abaixo. O estudo será publicado no Journal of Clinical Oncology no dia 20 deste mes.
A new class of targeted anti-cancer drugs that blocks the human epidermal growth factor (HER) receptor family shows promise in prolonging the lives of patients with recurrent prostate cancer, a new Cedars-Sinai study shows. The drug, a molecular targeted compound called pertuzumab, works by binding to and inhibiting the function of HER2 receptors, interrupting a key pathway that leads to cancer growth.
The study, published in the February 20 issue of the Journal of Clinical Oncology, involved 41 patients with treatment-resistant prostate cancer who had experienced progression of their disease after prior chemotherapy. Patients received the drug every three weeks until disease progression. MRI and CAT scans were used to evaluate the tumors during the period of drug therapy. While no shrinkage of tumors was reported, retrospective analysis showed that survival rate was prolonged to 16.4 months with the drug as compared to a median average of 10.7 months in a historical control group with similar baseline prognostic features.
“Advanced prostate cancer is difficult to treat – and the drug therapies currently available to these patients have not been very effective, especially in patients whose disease has progressed after chemotherapy treatment,” said David B. Agus, M.D., principal investigator of the study and research director of Cedars-Sinai’s Louis Warschaw Prostate Cancer Center at the Samuel Oschin Comprehensive Cancer Institute. “Pertuzumab may offer a new treatment approach for these patients when it is evaluated as a tool to slow – not stop or shrink -- tumor growth.”
“The theory is that by significantly slowing progression of the cancer, patients will experience a good quality of life for a longer period of time,” said Agus. “Ultimately, we hope drugs like pertuzumab will help us reach the point where cancer can be viewed as a lifetime disease to be managed much like AIDS is looked at now. This would be major shift from the current paradigm for cancer treatment, and is a promising area of research. This study must be viewed cautiously, however, as we are comparing statistics from historical control groups.”
Pertuzumab is a single-agent antibody designed to bind to the HER2 receptor and inhibit the ability of HER2 to pair with other HER family members (HER1, HER2, HER3 and HER4). If the pairing process (called dimerization) is not interrupted, the binding of these growth factors activates an intracellular signaling pathway that leads to tumor proliferation.
While other drugs such as docetaxel have shown to benefit men with advanced prostate cancer, no other second-line therapy (a treatment given when an initial treatment (first-line therapy) does not work or stops working) to date has shown to prolong survival.
Previous research published by cancer researchers at Cedars-Sinai and other institutions has shown that pertuzumab affects the growth of several other types of cancers, including breast, ovarian and lung cancer, and that the drug may also prolong survival for patients with advanced ovarian cancer.
In the current study, the pertuzumab was well-tolerated but no objective tumor shrinkages were observed. No decline in PSA (prostate-specific antigen; a tumor marker) levels was detected in patients during the study. According to the researchers, this study raises a question long debated in prostate cancer literature: what should clinical outcome standards or end point be the for studies involving patients with advanced, intractable prostate cancer who have limited treatment options.
The next step for researchers is to test the pertuzumab on a larger group of patients in a randomized fashion, and to analyze data that is not retrospective.
Prostate cancer is the most common type of cancer found in American men, other than skin cancer and is the second leading cause of cancer death in men. The American Cancer Society estimates that there will be about 218,890 new cases of prostate cancer in the United States in 2007 and that approximately 27,050 men will die of this disease. -Cedars-Sinai Medical Center
- Orientações Para Os Pacientes De Câncer Da Próstata E Suas Famílias
A sociedade americana contra o câncer publicou uma utilíssima série de orientações para os pacientes e suas famílias. Por essa razão as reproduzo abaixo. Como não tenho assistentes nem anunciantes, faço tudo só e o meu tempo é...
- Novo Clinical Trial Com Desatinib Para Pacientes Avançados
Há um Clinical Trial que está sendo iniciado, chamado Ready, para pacientes com cânceres muito avançados, necessitando tratamento quimioterápico. A descrição, que inclui os critérios de inclusão e de exclusão vão a seguir. Infelizmente, não...
- Experimento (clinical Trial Phase Iii) Com Abiraterona
...
- Vacinas E "clinical Trials" Para Câncer De Próstata Avançado
Atendendo a um pedido de parentes de paciente muito avançado fiz uma busca sobre os clinical trials com vacinas. Os resultados seguem abaixo. Um procedimento que muitos médicos americanos recomendam a seus pacientes com câncer muito avançado e que...
- Combinação De Terapias: Radiação Externa E Implantes Radioativos
Um trabalho publicado recentemente no International Journal of Radiation Oncology Biology Physics descreve os efeitos da combinação entre radioterapia externa e implantes. Acompanharam 232 homens durante 15 anos. Os resultados foram bons e estão descritos...
Saúde
Mais uma droga, pertuzumab
Pertuzumab poderá passar a ser a última linha na ampliação da vida de pacientes com câncer de próstata. Há muitos anos, o tratamento hormonal foi introduzido quando os demais tratamentos convencionais não curavam o câncer, que voltava. Não cura, mas aumenta a sobrevida em muitos meses até alguns anos. Taxotere foi adicionado depois, o que representoumais alguns meses de vida. Agora está sendo testado o pertuzumab.Um pequeno teste revelou que a droga prolongou a vida em 16,4 meses em um grupo que já havia tentado tudo o que havia para tentar. Entre os que não tomaram pertuzumab, a mediana até a morte foi de 10,7 meses. Um ganho de quase seis meses. Notícia mais detalhada abaixo. O estudo será publicado no Journal of Clinical Oncology no dia 20 deste mes.
A new class of targeted anti-cancer drugs that blocks the human epidermal growth factor (HER) receptor family shows promise in prolonging the lives of patients with recurrent prostate cancer, a new Cedars-Sinai study shows. The drug, a molecular targeted compound called pertuzumab, works by binding to and inhibiting the function of HER2 receptors, interrupting a key pathway that leads to cancer growth.
The study, published in the February 20 issue of the Journal of Clinical Oncology, involved 41 patients with treatment-resistant prostate cancer who had experienced progression of their disease after prior chemotherapy. Patients received the drug every three weeks until disease progression. MRI and CAT scans were used to evaluate the tumors during the period of drug therapy. While no shrinkage of tumors was reported, retrospective analysis showed that survival rate was prolonged to 16.4 months with the drug as compared to a median average of 10.7 months in a historical control group with similar baseline prognostic features.
“Advanced prostate cancer is difficult to treat – and the drug therapies currently available to these patients have not been very effective, especially in patients whose disease has progressed after chemotherapy treatment,” said David B. Agus, M.D., principal investigator of the study and research director of Cedars-Sinai’s Louis Warschaw Prostate Cancer Center at the Samuel Oschin Comprehensive Cancer Institute. “Pertuzumab may offer a new treatment approach for these patients when it is evaluated as a tool to slow – not stop or shrink -- tumor growth.”
“The theory is that by significantly slowing progression of the cancer, patients will experience a good quality of life for a longer period of time,” said Agus. “Ultimately, we hope drugs like pertuzumab will help us reach the point where cancer can be viewed as a lifetime disease to be managed much like AIDS is looked at now. This would be major shift from the current paradigm for cancer treatment, and is a promising area of research. This study must be viewed cautiously, however, as we are comparing statistics from historical control groups.”
Pertuzumab is a single-agent antibody designed to bind to the HER2 receptor and inhibit the ability of HER2 to pair with other HER family members (HER1, HER2, HER3 and HER4). If the pairing process (called dimerization) is not interrupted, the binding of these growth factors activates an intracellular signaling pathway that leads to tumor proliferation.
While other drugs such as docetaxel have shown to benefit men with advanced prostate cancer, no other second-line therapy (a treatment given when an initial treatment (first-line therapy) does not work or stops working) to date has shown to prolong survival.
Previous research published by cancer researchers at Cedars-Sinai and other institutions has shown that pertuzumab affects the growth of several other types of cancers, including breast, ovarian and lung cancer, and that the drug may also prolong survival for patients with advanced ovarian cancer.
In the current study, the pertuzumab was well-tolerated but no objective tumor shrinkages were observed. No decline in PSA (prostate-specific antigen; a tumor marker) levels was detected in patients during the study. According to the researchers, this study raises a question long debated in prostate cancer literature: what should clinical outcome standards or end point be the for studies involving patients with advanced, intractable prostate cancer who have limited treatment options.
The next step for researchers is to test the pertuzumab on a larger group of patients in a randomized fashion, and to analyze data that is not retrospective.
Prostate cancer is the most common type of cancer found in American men, other than skin cancer and is the second leading cause of cancer death in men. The American Cancer Society estimates that there will be about 218,890 new cases of prostate cancer in the United States in 2007 and that approximately 27,050 men will die of this disease. -Cedars-Sinai Medical Center
loading...
- Orientações Para Os Pacientes De Câncer Da Próstata E Suas Famílias
A sociedade americana contra o câncer publicou uma utilíssima série de orientações para os pacientes e suas famílias. Por essa razão as reproduzo abaixo. Como não tenho assistentes nem anunciantes, faço tudo só e o meu tempo é...
- Novo Clinical Trial Com Desatinib Para Pacientes Avançados
Há um Clinical Trial que está sendo iniciado, chamado Ready, para pacientes com cânceres muito avançados, necessitando tratamento quimioterápico. A descrição, que inclui os critérios de inclusão e de exclusão vão a seguir. Infelizmente, não...
- Experimento (clinical Trial Phase Iii) Com Abiraterona
...
- Vacinas E "clinical Trials" Para Câncer De Próstata Avançado
Atendendo a um pedido de parentes de paciente muito avançado fiz uma busca sobre os clinical trials com vacinas. Os resultados seguem abaixo. Um procedimento que muitos médicos americanos recomendam a seus pacientes com câncer muito avançado e que...
- Combinação De Terapias: Radiação Externa E Implantes Radioativos
Um trabalho publicado recentemente no International Journal of Radiation Oncology Biology Physics descreve os efeitos da combinação entre radioterapia externa e implantes. Acompanharam 232 homens durante 15 anos. Os resultados foram bons e estão descritos...